Flora Growth (FLGC) 10-Q10 Aug 232023 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 03, 2023
Cover [Abstract]
Entity Registrant Name	Flora Growth Corp.
Entity Central Index Key	0001790169
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Quarterly Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		6,854,596
Entity File Number	000-52776
Entity Incorporation State Country Code	A6
Entity Address Address Line 1	3406 SW 26th Terrace
Entity Address Address Line 2	Suite C-1
Entity Address City Or Town	Fort Lauderdale
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33132
City Area Code	954
Local Phone Number	842-4989
Security 12b Title	Common Shares, no par value
Trading Symbol	FLGC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false

Unaudited Condensed Interim Con

Unaudited Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash	$ 1,782	$ 8,935
Restricted cash	25	0
Trade and amounts receivable, net of $1,346 allowance ($1,385 at December 31, 2022)	4,854	5,259
Loans receivable and advances	0	271
Prepaid expenses and other current assets	1,765	805
Indemnification receivables	3,374	3,429
Inventory	8,684	8,747
Current assets held for sale	1,778	3,709
Total current assets	22,262	31,155
Non-current
Property, plant and equipment	951	1,218
Operating lease right of use assets	1,086	2,118
Intangible assets	5,717	17,739
Goodwill	0	23,372
Investments	200	730
Other assets	263	263
Noncurrent assets held for sale	0	4,392
Total assets	30,479	80,987
Current
Trade payables	6,617	7,831
Contingencies	5,188	5,044
Current portion of debt	1,200	1,086
Current portion of operating lease liability	1,124	1,116
Other accrued liabilities	2,523	1,760
Current liabilities held for sale	1,175	610
Total current liabilities	17,827	17,447
Non-current
Non-current operating lease liability	1,053	1,561
Deferred tax	523	1,712
Contingent purchase considerations	848	3,547
Noncurrent liabilities held for sale	0	308
Total liabilities	20,251	24,575
SHAREHOLDERS' EQUITY
Share capital, no par value, unlimited authorized, 6,859 issued and outstanding (6,776 at December 31, 2022)	0	0
Additional paid-in capital	150,726	150,420
Accumulated other comprehensive loss	(1,526)	(2,732)
Deficit	(138,266)	(90,865)
Total Flora Growth Corp. shareholders' equity	10,934	56,823
Non-controlling interest in subsidiaries	(706)	(411)
Total shareholders' equity	10,228	56,412
Total liabilities and shareholders' equity	$ 30,479	$ 80,987

Unaudited Condensed Interim C_2

Unaudited Condensed Interim Consolidated Statements of Financial Position (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Unaudited Condensed Interim Consolidated Statements of Financial Position
Trade and amounts receivable, allowance	$ 1,346	$ 1,385
Share capital, shares issued	6,859	6,776
Share capital, shares outstanding	6,859	6,776

Unaudited Condensed Interim C_3

Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
Revenue	$ 21,460	$ 8,943	$ 40,779	$ 13,144
Cost of sales	17,500	5,624	31,473	7,597
Gross profit	3,960	3,319	9,306	5,547
Operating expenses
Consulting and management fees	3,662	2,116	7,333	3,976
Professional fees	668	727	665	1,705
General and administrative	685	1,088	1,036	1,660
Promotion and communication	1,263	2,039	2,571	4,414
Travel expenses	124	291	256	492
Share based compensation	338	1,263	992	2,789
Research and development	13	111	29	233
Operating lease expense	308	136	624	327
Depreciation and amortization	874	706	1,738	1,050
Bad debt expense	18	254	47	255
Asset impairment	34,941	15,652	34,941	15,652
Other expenses (income), net	1,127	456	1,505	810
Total operating expenses	44,021	24,839	51,737	33,363
Operating loss	(40,061)	(21,520)	(42,431)	(27,816)
Interest expense (income)	28	(12)	51	(42)
Foreign exchange (gain) loss	(164)	211	(176)	200
Unrealized (gain) loss from changes in fair value	(1,815)	1,333	(932)	1,333
Net loss before income taxes and discontinued operations	(38,110)	(23,052)	(41,374)	(29,307)
Income Tax Expense (Benefit)	(1,119)	0	(1,196)	0
Net loss from continuing operations	(36,991)	(23,052)	(40,178)	(29,307)
Loss from discontinued operations, net of taxes	(7,565)	(1,620)	(8,283)	(2,995)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total	(44,556)	(24,672)	(48,461)	(32,302)
Other comprehensive gain (loss)
Exchange differences on foreign operations, net of income taxes of $nil ($nil in 2022)	849	10	1,206	(567)
Total comprehensive loss for the period	(43,707)	(24,662)	(47,255)	(32,869)
Net loss attributable to:
Flora Growth Corp. continuing operations	(36,991)	(23,052)	(40,178)	(29,307)
Flora Growth Corp. discontinued operations	(7,299)	(1,579)	(7,988)	(2,890)
Non-controlling interests in subsidiaries	(266)	(41)	(295)	(105)
Comprehensive loss attributable to:
Flora Growth Corp.	(43,441)	(24,621)	(46,960)	(32,764)
Non-controlling interests in subsidiaries	$ (266)	$ (41)	$ (295)	$ (105)
Basic loss per share from continuing operations	$ (5.5)	$ (6.01)	$ (6.01)	$ (8.01)
Diluted loss per share from continuing operations	(5.5)	(6.01)	(6.01)	(8.01)
Basic loss per share from discontinued operations	(1.09)	(0.41)	(1.2)	(0.79)
Diluted loss per share from discontinued operations	(1.09)	(0.41)	(1.2)	(0.79)
Basic loss per share attributable to Flora Growth Corp.	(6.58)	(6.42)	(7.21)	(8.8)
Diluted loss per share attributable to Flora Growth Corp.	$ (6.58)	$ (6.42)	$ (7.21)	$ (8.8)
Weighted average number of common shares outstanding - basic	6,726	3,836	6,684	3,659
Weighted average number of common shares outstanding - diluted	6,726	3,836	6,684	3,659

Unaudited Condensed Interim C_4

Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) - USD ($) $ in Thousands	Common shares	Additional paid-in capital	Accumulated other comprehensive (loss) income	Accumulated deficit	Non-controlling interests in subsidiaries (deficiency)	Total
Balance, shares at Dec. 31, 2021	3,276
Balance, amount at Dec. 31, 2021	$ 0	$ 116,810	$ (1,108)	$ (38,536)	$ (225)	$ 76,941
Common shares issued for business combinations, shares	475
Common shares issued for business combinations, amount		14,697				14,697
Common shares issued for other agreements, shares	5
Common shares issued for other agreements, amount		272				272
Acquisition of noncontrolling interest, shares	6
Acquisition of noncontrolling interest, amount		283		(365)	28	(54)
Options issued		1,443				1,443
Options exercised, shares	17
Options exercised, amount		50				50
Warrants exercised, shares	3
Warrants exercised, amount		28				28
Share issuance costs		(79)				(79)
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)			(577)			(577)
Net loss				(7,566)	(64)	(7,630)
Balance, shares at Mar. 31, 2022	3,782
Balance, amount at Mar. 31, 2022	$ 0	133,504	(1,685)	(46,467)	(261)	85,091
Share repurchase		(250)				(250)
Equity issued for other agreements, shares	35
Equity issued for other agreements, amount		1,281				1,281
Options issued		1,263				1,263
Options exercised, shares	9
Options exercised, amount		27				27
Warrants exercised, shares	21
Warrants exercised, amount		63				63
Warrants expired/cancelled	0
Share issuance costs		4				4
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)			10			10
Net loss				(24,631)	(41)	(24,672)
Balance, shares at Jun. 30, 2022	3,847
Balance, amount at Jun. 30, 2022		135,892	(1,675)	(71,098)	(302)	62,817
Balance, shares at Dec. 31, 2022	6,776
Balance, amount at Dec. 31, 2022	$ 0	150,420	(2,732)	(90,865)	(411)	56,412
Equity issued for other agreements, shares	16
Equity issued for other agreements, amount		95				95
Options issued		119				119
Options expired/cancelled		(765)		765
Restricted units granted, amount	$ 52	534				534
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)			357			357
Net loss				(3,876)	(29)	(3,905)
Balance, shares at Mar. 31, 2023	6,844
Balance, amount at Mar. 31, 2023	$ 0	150,403	(2,375)	(93,976)	(440)	53,612
Balance, shares at Dec. 31, 2022	6,776
Balance, amount at Dec. 31, 2022	$ 0	150,420	(2,732)	(90,865)	(411)	56,412
Balance, shares at Jun. 30, 2023	6,859
Balance, amount at Jun. 30, 2023		150,726	(1,526)	(138,266)	(706)	10,228
Balance, shares at Mar. 31, 2023	6,844
Balance, amount at Mar. 31, 2023	$ 0	150,403	(2,375)	(93,976)	(440)	53,612
Equity issued for other agreements, shares	110
Equity issued for other agreements, amount		447				447
Options issued		92				92
Options expired/cancelled		(258)				(258)
Restricted units granted, shares	60
Restricted units granted, amount		838				838
Restricted stock cancelled, shares	(155)
Restricted stock cancelled, amount		(779)				(779)
Share issuance costs		(17)				(17)
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)			849
Net loss				(44,290)	(266)	(44,556)
Balance, shares at Jun. 30, 2023	6,859
Balance, amount at Jun. 30, 2023		$ 150,726	$ (1,526)	$ (138,266)	$ (706)	$ 10,228

Unaudited Condensed Interim C_5

Unaudited Condensed Interim Consolidated Statement of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (48,461)	$ (32,302)
Adjustments to net loss:
Depreciation and amortization	1,886	1,346
Share based compensation	992	2,978
Asset impairment	39,645	15,652
Changes in fair value of investments and liabilities	(932)	1,333
Bad debt expense	612	405
Interest expense (income)	54	(14)
Interest paid	(54)	(69)
Income tax recovery	(1,185)	0
Net income (loss) to cash provided by (Used in) operating activities	(7,443)	(10,671)
Net change in non-cash working capital:
Trade and other receivables	1,152	802
Inventory	932	(745)
Prepaid expenses and other assets	(936)	(33)
Trade payables and accrued liabilities	(1,488)	(341)
Net cash used in operating activities	(7,783)	(10,988)
Cash flows from financing activities:
Equity issue costs	(17)	(75)
Exercise of warrants and options	0	168
Common shares repurchased	0	(250)
Loan borrowings	206	212
Loan repayments	(77)	(82)
Net cash provided (used) by financing activities	112	(27)
Cash flows from investing activities:
Purchases of property, plant and equipment and intangible assets	(195)	(723)
Business and asset acquisitions, net of cash acquired	0	(15,457)
Net cash used in investing activities	(195)	(16,180)
Effect of exchange rate on changes on cash	584	(152)
Change in cash during the period	(7,282)	(27,347)
Cash and restricted cash at beginning of period	9,537	37,616
Cash included in assets held for sale	(448)	(381)
Cash and restricted cash at end of period	1,807	9,888
Supplemental disclosure of non-cash investing and financing activities
Common shares issued for business combinations	$ 0	$ 14,917
Assets acquired for contingent consideration	303	0
Common shares issued for other agreements	95	1,281
Operating lease additions to right of use assets	97	2,053

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
NATURE OF OPERATIONS	Jun. 30, 2023
Nature Of Operations And Going Concern [Abstract]
NATURE OF OPERATIONS [Text Block]	1. NATURE OF OPERATIONS Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is manufacturer, distributor and an all-outdoor cultivator of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3406 SW 26th Terrace, Suite C-1, Fort Lauderdale, Florida 3312. Presentation of comparative financial statements On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 13.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION [Text Block]	2. BASIS OF PRESENTATION These unaudited condensed interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2022. These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. These unaudited condensed interim consolidated financial statements apply the same accounting policies as those used in the financial statements included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2022. These interim condensed consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP. Going concern The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash of $1.8 million at June 30, 2023, net loss of $48.5 million for the six months ended June 30, 2023, and an accumulated deficit of $138.3 million at June 30, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these interim condensed consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Basis of consolidation These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. The Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2022. On July 5, 2023, the Company sold its shares in its Colombian related subsidiaries. The results of these subsidiaries are included in discontinued operations in the accompanying unaudited condensed interim consolidated financial statements. See discussion in Note 3.

ASSETS HELD FOR SALE AND DISCON

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS	6 Months Ended
ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS [Text Block]	3. On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business. The Company has received proceeds of CAD $0.5 million subsequent to period-end and expects to receive the remaining proceeds upon closing of the transaction. See discussion in Note 20. The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations. The Company has presented the associated assets and liabilities of the Colombian subsidiaries as held for sale. The major classes of assets and liabilities classified as held for sale as of June 30, 2023 and December 31, 2022 were as follows: June 30, 2023 December 31, 2022 Assets held for sale Cash $ 448 $ 602 Trade and amounts receivable 633 1,592 Prepaid expenses and other current assets 115 174 Inventory 582 1,341 Total current assets held for sale 1,778 3,709 Property, plant and equipment - 3,592 Operating lease right of use assets - 419 Intangible assets - 358 Other assets - 23 Total noncurrent assets held for sale - 4,392 Total assets held for sale $ 1,778 $ 8,101 Liabilities held for sale Current portion of long-term debt $ 38 $ - Current portion of operating lease liability 370 72 Other accrued liabilities 767 538 Total current liabilities held for sale 1,175 610 Non-current operating lease liability - 308 Total liabilities held for sale $ 1,175 $ 918 The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, for the three and six months ended June 30, 2023 and 2022: For the three For the three For the six For the six Revenue $ 662 $ 1,028 $ 1,450 $ 1,773 Cost of sales 466 471 1,123 774 Gross profit from discontinued operations 196 557 327 999 Consulting and management fees 307 683 676 1,267 Professional fees 46 120 82 391 General and administrative 105 419 282 769 Promotion and communication 8 131 14 305 Operating lease expense 43 106 93 122 Depreciation and amortization 70 186 148 296 Bad debt expense 565 150 565 150 Asset impairment 4,704 - 4,704 - Other (income) expense 2 363 124 666 Operating loss from discontinued operations (5,654 ) (1,601 ) (6,361 ) (2,967 ) Interest (income) expense 2 19 2 28 Net loss before income taxes (5,656 ) (1,620 ) (6,363 ) (2,995 ) Loss on disposal of discontinued operations 1,909 - 1,909 - Income tax expense - - 11 - Loss from discontinued operations $ (7,565 ) $ (1,620 ) $ (8,283 ) $ (2,995 ) The following table summarizes the significant operating and investing items related to the Colombian subsidiaries for the six months ended June 30, 2023 and 2022 For the six For the six Operating activities of discontinued operations Depreciation and amortization $ 148 $ 296 Bad debt expense 565 150 Asset impairment 4,704 - Investing activities of discontinued operations Purchases of property, plant and equipment $ 92 $ 579 The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., and Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment. The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations. During the three and six months ended June 30, 2023, the Company recorded a loss on disposal of $1.9 million as the carrying value of the assets being sold exceeded the expected sale price.

TRADE AND AMOUNTS RECEIVABLE

TRADE AND AMOUNTS RECEIVABLE	6 Months Ended
TRADE AND AMOUNTS RECEIVABLE	Jun. 30, 2023
Trade And Other Receivables [Abstract]
TRADE AND AMOUNTS RECEIVABLE [Text Block]	4. The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at June 30, 2023 and December 31, 2022 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables. June 30, 2023 December 31, 2022 Trade accounts receivable $ 3,894 $ 4,288 Allowance for expected credit losses (1,346 ) (1,385 ) HST/VAT receivable 2,126 2,294 Other receivables 180 62 Total $ 4,854 $ 5,259 Changes in the trade accounts receivable allowance in the three and six months ended June 30, 2023 relate to establishing an allowance for expected credit losses and reclassification of assets held for sale. There was $0.1 million in write-offs of trade receivables during the three and six months ended June 30, 2023. The Company has no amounts written-off that are still subject to collection enforcement activity as at June 30, 2023. The Company's aging of trade accounts receivable is as follows: June 30, 2023 Current $ 672 1-30 Days 924 31-60 Days 432 61-90 Days 197 91-180 Days 570 180+ Days 1,099 Total trade receivables $ 3,894

INVENTORY

INVENTORY	6 Months Ended
INVENTORY	Jun. 30, 2023
Inventory Disclosure [Abstract]
INVENTORY [Text Block]	5. INVENTORY Inventory is comprised of the following as at June 30, 2023 and 2022: June 30, 2023 December 31, 2022 Raw materials and supplies $ 1,669 $ 2,363 Finished goods 7,015 6,384 Total $ 8,684 $ 8,747

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
PROPERTY, PLANT AND EQUIPMENT	Jun. 30, 2023
PROPERTY PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT [Text Block]	6. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consist of the following: June 30, 2023 December 31, 2022 Land $ 296 $ 291 Buildings - - Machinery and office equipment 759 1,098 Vehicles 81 37 Total 1,136 1,426 Less: accumulated depreciation (185 ) (208 ) Property, plant and equipment, net $ 951 $ 1,218 Depreciation expense for the three and six months ended June 30, 2023 was less than $ million and $0.1 million, respectively, (June 30, 2022 - $ million and $0.1 million, respectively) and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of operations and comprehensive loss. An impairment of $0.2 million was recorded against Property, Plant and Equipment during the three and six months ended June 30, 2023. See Note 10.

INVESTMENTS

INVESTMENTS	6 Months Ended
INVESTMENTS	Jun. 30, 2023
INVESTMENTS
INVESTMENTS [Text Block]	7. As at June 30, 2023, the Company's investments consisted of common shares and warrants in an early-stage European cannabis company. The Company owned approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of other investors. The Company did not exercise the warrants and they expired on February 1, 2023 . The Company recorded the remaining value of the warrants as a loss on changes in fair value of the investment during the six months ended June 30, 2023. Due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors, the Company determined that impairment indicators were present at June 30, 2023. The initial investment multiples were compared to the guideline public company multiples observed as at June 30, 2023 (0.4 price to book value and 0.5 price to tangible value), with these updated valuation multiples applied to the investee's estimated book value. The Company also considered the status of the investee's milestones since the purchase date, as well as recent transactions in the European cannabis market for indicators of change in value. The Company determined there has been a rapid decline in value of certain European cannabis assets, and, thus, recorded an impairment of the investment totaling $0.5 million during the period ending June 30, 2023. The impairment valuation model for the common shares uses Level 3 inputs of the fair value hierarchy. A schedule of the Company's investments activity is as follows: Investee common shares Warrants CAD 0.30 exercise price Warrants CAD 1.00 exercise price Total Financial asset hierarchy level Level 3 Level 3 Level 3 Balance at December 31, 2022 $ 730 $ 34 $ - $ 764 Loss on changes in fair value (530 ) (34 ) - (564 ) Balance at June 30, 2023 $ 200 $ - $ - $ 200 The loss on changes in fair value appears in the unrealized (gain) loss on changes in fair value caption in the unaudited condensed interim consolidated statements of loss and comprehensive loss. The value of the investee common shares appears in the investment line on the unaudited condensed interim consolidated statement of financial position.

ASSET ACQUISITIONS AND BUSINESS

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS	6 Months Ended
ASSET ACQUISITIONS AND BUSINESS COMBINATIONS	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Text Block]	8. Original Hemp asset acquisition On March 1, 2023, the Company completed its acquisition of all the assets operating under the brand "Original Hemp". The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Original Hemp did not meet the definition of a business as it did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the transaction has been accounted for as an asset acquisition whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. Total purchase consideration was $0.3 million. As consideration for the purchased assets of Original Hemp, the Company will pay an amount equal to 50% of the net profits received in connection with the sale of Original Hemp products until such a time that the Company will have paid a total of $0.2 million. Once the Company has paid $0.2 million, the Company will pay an amount equal to 10% of the net profits received in connection with the sale of Original Hemp products until such a time that the Company will have paid an additional amount of $0.4 million. As these entire amounts are considered contingent consideration, it was valued using discounted cash flow models utilizing two different rates, high and low. The significant inputs to the valuation include the estimated seven-year time period to accumulate the $0.6 million maximum payment and discount rates of 31.5%, high, and 17.0%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.3 million contingent purchase consideration is classified within the contingent purchase considerations line on the statement of financial position. At June 30, 2023, the remaining balance outstanding was $0.3 million. The purchase is accounted for as an asset acquisition with amounts allocated as at the acquisition date to each major class of assets as follows: Inventory $ 109 Intangible asset 194 Total net assets acquired $ 303 Franchise Global Health Inc. ("FGH") business combination On December 23, 2022, the Company completed its acquisition of all the issued and outstanding common shares (the "Franchise Common Shares") of FGH., a corporation existing under the laws of the Province of British Columbia, by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly owned subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industry with principal operations in Germany. The Company acquired FGH to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in Germany and to improve synergies and cost savings. The purchase consideration was comprised of 2,176,297 of Flora's common shares (the "Flora Shares"), valued at $9.8 million, inclusive of a 7.5% fair value discount for the required ninety (90) day restrictive legend on the Flora Shares delivered to the former shareholders of FGH. The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows: Current assets Cash $ 730 Trade receivables 2,271 Inventory 2,019 Indemnity receivables 3,415 Prepaid assets 139 Non-current assets Property, plant, and equipment 452 Right of use assets 115 Intangible asset 6,102 Goodwill 3,716 Total assets $ 18,959 Current liabilities Trade payables and accrued liabilities $ (6,245 ) Current lease liabilities (98 ) Current portion of debt (1,062 ) Long term lease liability (21 ) Deferred tax (1,717 ) Total liabilities $ (9,143 ) Total net assets acquired $ 9,816 The amounts shown are provisional. The Company has a measurement period of one year following the acquisition date on December 23, 2022 to adjust the provisional amounts recognized for any new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of additional assets or liabilities, or affected the measurement of the amounts recognized as of that date. As part of the acquisition terms, Clifford Starke, the Company's current Chief Executive Officer and a Director and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. A total of $3.4 million of liabilities were recognized in the trade payables and accrued liabilities of FGH on the date of acquisition that were subject to this indemnification obligation. The Company believes it will be fully indemnified by the current CEO of Flora, and, as such, has recorded $3.4 million of indemnification receivables. The indemnified losses include: 1. 2. 3. The intangible assets of $6.1 million were comprised of the following categories and estimated useful lives: supplier relationships of $2.4 million for five years, customer relationships of $2.3 million for five years, and licenses of $1.4 million for five years. The Company does not expect the goodwill and intangible asset values to be deductible for Canadian income tax purposes. The goodwill is assigned to the commercial and wholesale segment. Just Brands LLC and High Roller Private Label LLC (collectively "JustCBD") business combination On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC for total purchase consideration of $37.0 million. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams. JustCBD is based in Florida in the United States and was formed in 2017. The Company acquired JustCBD to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in the United States and for the acquisition of human capital through JustCBD's management team. The purchase consideration was comprised of (i) $16.0 million of cash, less $0.2 million returned to the Company in August 2022 due to final calculated closing working capital falling short of the target working capital, (ii) 475,000 common shares of the Company valued at $14.7 million, inclusive of a 15% fair value discount for the required six-month holding period of the shares, and (iii) $4.0 million of contingent purchase consideration. The contingent purchase consideration is based on a clause in the purchase agreement that provides that if at any time during the 24 months following the acquisition date, the five-day volume weighted average price ("VWAP") per share of the Company's common shares as quoted on the Nasdaq Capital Market fails to equal or exceed $100.00, then the Company shall issue a number of additional common shares to the sellers equal to the difference between (x) a fraction, the numerator of which is $47.5 million and the denominator of which is the highest five day VWAP at any point during the 24 months following the closing and (y) the 475,000 common shares delivered to the sellers at the closing. In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500 shares to the sellers ("Excess Shares") and the Company shall not have obtained shareholder consent, if required, the Company may deliver cash to the sellers in lieu of such Excess Shares determined by a formula set forth in the purchase agreement. The contingent purchase consideration was classified as a financial liability within the contingent purchase considerations line on the statement of financial position as the Company may be required to settle any amounts due in cash instead of common shares if the Company's common shareholders do not provide requisite shareholder approval to issue additional common shares. It is now included in the other accrued liabilities line on the statement of financial position as the settlement date is within the next 12 months. The fair value of the contingent purchase consideration at February 24, 2022 was determined using a Monte Carlo simulation incorporating Brownian motion with 100,000 trials through a binomial model. The significant inputs to the valuation included the two-year time period, the Company's closing share price at February 24, 2022 ($36.40), estimated Company common share volatility (100%), and risk-free rate of 1.5% to discount the ending result to present value. The fair value of the contingent purchase consideration at June 30, 2023 was determined using a Monte Carlo simulation incorporating Brownian motion with 100,000 trials through a binomial model. The significant inputs to the valuation include the remaining time period, the Company's closing share price at June 30, 2023 ($2.38), estimated Company common share volatility (110%), and risk-free rate of 5.5% to discount the ending result to present value. The Company determined that the balance of this contingent consideration at June 30, 2023 was $1.5 million, with the $1.1 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the unaudited condensed interim consolidated statements of loss and comprehensive loss. The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows: Current assets Cash $ 535 Trade receivables 975 Inventory 5,534 Other current assets 540 Non-current assets Property, plant, and equipment 536 Right of use assets 772 Other non-current assets 127 Intangible asset 4,533 Goodwill 24,898 Total assets $ 38,450 Current liabilities Trade payables and accrued liabilities $ (2,273 ) Current lease liabilities (644 ) Provision for sales tax (982 ) Deferred tax (24 ) Other current liabilities (99 ) Total liabilities $ (4,022 ) Total net assets acquired $ 34,428 The fair value of the trade receivables reflects a $0.3 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. The acquired provision for sales tax is discussed at Note 16 below. The intangible assets of $4.5 million are comprised of the following categories and estimated useful lives: tradenames of $3.1 million for eight to nine years, customer relationships of $1.2 million for five to seven years, and know-how of $0.2 million for three years. The Company expects the goodwill and intangible asset values to be deductible for Unites States income tax purposes. The goodwill is assigned to the house of brands segment. No Cap Hemp Co. business combination On July 20, 2022, Just Brands LLC., a wholly owned subsidiary of the Company, acquired certain assets, assumed certain liabilities, retained certain employees and processes (together the "purchased assets") of No Cap Hemp Co. ("No Cap") for total purchase consideration of $0.9 million. No Cap is a manufacturer and distributor of high quality and affordable CBD products. No Cap is based in Florida in the United States and was formed in 2017. Just Brands LLC acquired No Cap to expand its product offerings and accelerate its revenue growth. As consideration for the purchased assets of No Cap, Just Brands LLC will pay an amount equal to 10% of the sales of No Cap until such a time that Just Brands LLC will have paid a total of $2.0 million. Also on July 20, 2022, Just Brands LLC advanced $0.2 million to the former owners of No Cap. This $0.2 million will be settled prior to and in the same manner as the consideration for the purchased assets. As these entire amounts are considered contingent consideration, it was valued using discounted cash flow models utilizing two different rates, high and low. The significant inputs to the original valuation included the estimated nine-year time period to accumulate the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million contingent purchase consideration is classified within the contingent purchase considerations line on the statement of financial position. The Company determined that the balance of this contingent consideration at June 30, 2023 was $0.5 million, with the $0.4 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the unaudited condensed interim consolidated statements of loss and comprehensive loss. The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows: Current assets Trade receivables $ 31 Inventory 725 Non-current assets Goodwill 417 Total assets $ 1,173 Current liabilities Trade payables and accrued liabilities (272 ) Total liabilities $ (272 ) Total net assets acquired $ 901 The fair value of the trade receivables reflects a $0.2 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. The Company expects the goodwill to be deductible for United States income tax purposes. The goodwill is assigned to the house of brands segment.

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	6 Months Ended
INTANGIBLE ASSETS AND GOODWILL	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL [Text Block]	9. INTANGIBLE ASSETS AND GOODWILL A continuity of intangible assets for the six months ended June 30, 2023 is as follows: License Customer/Supplier Relationships Trademarks Patents Non- Goodwill Total Cost At December 31, 2022 $ 1,396 $ 7,512 $ 5,154 $ 4,530 $ 1,190 $ 23,633 $ 43,415 Additions - 194 - - - - 194 Impairment (752 ) (4,418 ) (1,599 ) (3,432 ) (529 ) (23,372 ) (34,102 ) At June 30, 2023 $ 644 $ 3,288 $ 3,555 $ 1,098 $ 661 $ 261 $ 9,507 Accumulated Amortization At December 31, 2022 $ - $ 348 $ 618 $ 621 $ 463 $ - $ 2,050 Additions 142 663 319 277 198 - 1,599 At June 30, 2023 $ 142 $ 1,011 $ 937 $ 898 $ 661 $ - $ 3,649 Foreign currency translation 24 76 20 - - (261 ) (141 ) Net book value at June 30, 2023 $ 526 $ 2,353 $ 2,638 $ 200 $ - $ - $ 5,717 Amortization expense for the three and six months ended June 30, 2023 was $0.8 million and $1.6 million respectively (June 30, 2022 - $0.3 million and $0.9 million, respectively) and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss. At June 30, 2023, the weighted average amortization period remaining for intangible assets was 5.7 years. At June 30, 2023, the estimated future amortization expense related to intangible assets is as follows: 2023 $ 587 2024 1,173 2025 1,109 2026 1,096 2027 1,032 Thereafter 720 Total $ 5,717 The Company's goodwill is assigned to the following reporting units: Vessel JustCBD Franchise Total Gross goodwill recorded prior to December 31, 2022 $ 19,675 $ 25,038 $ 3,732 $ 48,445 Impairment recorded prior to December 31, 2022 (19,675 ) (5,398 ) - (25,073 ) Net book value as at December 31, 2022 - 19,640 3,732 23,372 Impairment recorded - (19,640 ) (3,732 ) (23,372 ) Net book value as at June 30, 2023 $ - $ - $ - $ -

IMPAIRMENT OF ASSETS

IMPAIRMENT OF ASSETS	6 Months Ended
IMPAIRMENT OF ASSETS	Jun. 30, 2023
Impairment Of Assets [Abstract]
IMPAIRMENT OF ASSETS [Text Block]	10. Goodwill The Company tests its goodwill for impairment as part of its annual fourth quarter impairment test, and at interim periods when impairment indicators exist. The Company's goodwill is assigned to the reporting units associated with the original acquisition of those operations. At June 30, 2023, the Company determined that indicators were present for its JustCBD and FGH reporting units due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the JustCBD reporting unit for impairment as at June 30, 2023 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $19.6 million recorded in the first half of fiscal 2023 within the Company's house of brands segment. The impairment is recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss. The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.8 million. The income approach used a discount rate of 32%, operating margins from 3% to 9%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and drop down to 3% in 2024 and thereafter. Likewise, the Company tested the FGH reporting unit for impairment as at June 30, 2023 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $3.7 million recorded in the first half of fiscal 2023 within the Company's commercial and wholesale segment. The impairment is recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss. The reporting unit's fair value was determined based on an income approach discounted cash flow model of $2.3 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter. Long-lived assets For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of June 30, 2023 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of property, plant and equipment, operating lease right of use assets, customer relationships, trademarks, patents and non-compete agreements within its Vessel asset group within the house of brands segment totaling $6.6 million. Likewise, the Company recorded an impairment of supplier relationships, customer relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $3.7 million. Finally, the Company recorded an impairment of customer relationships, trademarks and patents within its JustCBD asset group within the house of brands segment totaling $0.4 million. These charges were recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss.

DEBT

DEBT	6 Months Ended
DEBT	Jun. 30, 2023
Debt Disclosure [Abstract]
DEBT [Text Block]	11. Euro credit facility The Company, through FGH, has a credit facility for 1.0 million Euro with Hypoverinsbank, secured by the trade and other receivables of one of the subsidiaries of FGH. As of June 30, 2023, the outstanding amount was 1.0 million Euros ($1.1 million USD). The credit facility has a ra te of Euro Int erbank Offer Rate ("Euribor") plus % per year and was originally due . The Company and the bank agreed to renew the credit facility on January 10, 2023, under the same terms. The interest on the credit facility resets every two months and the interest on the outstanding balance is paid monthly. There arrangement is open ended without a predetermined maturity date. JustCBD insurance premium loan The Company, through JustCBD, entered into a loan agreement for $0.2 million with ClassicPlan Premium Financing, Inc, to finance the purchase of certain insurance policies. The loan is secured by the insurance policies, including all rights to cancel and to receive all unearned premiums, commissions, broker fees and other refunds arising out of these policies. As of June 30, 2023, the outstanding amount was $0.1 million. The loan has a rate of 10.1% per year and is due December 8, 2023 . The Company makes monthly principal and interest payments of less than $ million.

LEASES

LEASES	6 Months Ended
LEASES	Jun. 30, 2023
Leases [Abstract]
LEASES [Text Block]	12. LEASES The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through June 30, 2023. Information regarding the Company's leases is as follows: Three months ended June 30, 2023 Three months ended June 30, 2022 Six months ended June 30, 2023 Six months ended June 30, 2022 Components of lease expense Operating lease expense $ 308 $ 136 $ 624 $ 327 Short-term lease expense 62 82 135 233 Total lease expense $ 370 $ 218 $ 759 $ 560 Other Information Operating cash flows from operating leases $ 356 $ 216 $ 720 $ 489 ROU assets obtained in exchange for new operating lease liabilities - 2,097 97 2,825 Weighted-average remaining lease term in years for operating leases 3.4 4.5 Weighted-average discount rate for operating leases 7.7% 8.1% Maturities of operating lease liabilities as of June 30, 2023 are as follows: Thousands of United States dollars Operating Leases 2023 $ 1,234 2024 425 2025 396 2026 321 2027 48 Total future lease payments 2,424 Less: imputed interest (247 ) Total lease liabilities 2,177 Less: current lease liabilities (1,124 ) Total non-current lease liabilities $ 1,053 Most of the Company’s leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to two years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2023.

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended
SHARE CAPITAL	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
SHARE CAPITAL [Text Block]	13. SHARE CAPITAL Authorized and issued The Comp any is authoriz ed to issue an unlimited number of common shares, par value. The Company had the following significant common share transactions: Six months ended June 30, 2023 REVERSE STOCK SPLIT On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split"). Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common shares were automatically combined and reclassified into one issued and outstanding common share. The Reverse Stock Split did not affect any shareholder's ownership percentage of the common shares, alter the par value of the common shares or modify any voting rights or other terms of the common shares. The number of authorized shares of common shares under the Company's Articles remained unchanged. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional interest as a result of the Reverse Stock Split was rounded down to the nearest whole common share. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. OTHER ISSUANCES On January 31, 2023, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 16,250 common shares of the Company, valued at $0.1 million, to a third party to settle a legal dispute that arose in April 2019. See Note 16. On April 12, 2023, Luis Merchan tendered his resignation as both Chairman of the Board of Directors of the Company and as its Chief Executive Officer. On this date, the Company entered into a separation agreement with Mr. Merchan, pursuant to which the Company issued 80,000 common shares of the Company, valued at $0.4 million, on April 26, 2023, and 30,000 common shares of the Company, valued at $0.1 million, on May 14, 2023 to Mr. Merchan.

SHARE BASED COMPENSATION

SHARE BASED COMPENSATION	6 Months Ended
SHARE BASED COMPENSATION	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE BASED COMPENSATION [Text Block]	14. SHARE BASED COMPENSATION The Company's 2022 Incentive Compensation Plan (the "2022 Plan") and its previous "'rolling" stock option plan (the "Prior Plan") are described in the Company's 2022 Form 10-K. OPTIONS Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Compensation Committee of the Company's Board of Directors. Common shares are newly issued from available authorized shares upon exercise of awards. The Company no longer makes new grants of stock options under the Prior Plan. Information relating to share options outstanding and exercisable as at June 30, 2023 and December 31, 2021 is as follows: Options Outstanding Number of Weighted Weighted average Aggregate Outstanding balance, December 31, 2022 290 $ 34.17 4.2 $ 64 Granted 5 $ 7.00 9.7 - Cancelled (75 ) $ 24.75 6.0 - Outstanding balance, June 30, 2023 220 $ 36.79 3.0 $ - Exercisable balance, June 30, 2023 203 $ 38.86 2.6 $ - The total benefit related to the options granted in the three and six months ended June 30, 2023 was ($0.2) million and less than ($0.1) million, respectively (2022 total expense - $1.3 million and $2.8 million, respectively). The benefit is the result of non-vested options cancelled during the period. This (benefit) expense is included in the share-based compensation line on the statement of comprehensive loss. Generally, the options granted in 2023 and 2022 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company. At June 30, 2023 the total remaining stock option cost for nonvested awards is expected to be $0.1 million over a weighted average future period of 1.2 years until the awards vest. See Note 20 for subsequent forfeiture of options. RESTRICTED STOCK AWARDS Information relating to restricted stock awards outstanding as at June 30, 2023 and December 31, 2022: Number of Weighted Thousands Balance, December 31, 2022 146 $ 13.64 Granted 112 5.85 Vested (38 ) (13.74 ) Cancelled (155 ) (9.17 ) Balance, June 30, 2023 65 $ 11.22 The total expense related to the restricted stock awards in the three and six months ended June 30, 2023 was $0.1 million and $0.6 million (2022 - nil The outstanding restricted stock awards vest over the next three years provided the award holder is still employed or engaged by the Company. As of June 30, 2023, the Company had $0.2 million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next three years. See Note 20 for subsequent forfeiture of restricted share awards.

WARRANTS

WARRANTS	6 Months Ended
WARRANTS	Jun. 30, 2023
Warrants [Abstract]
WARRANTS [Text Block]	15. WARRANTS The following summarizes the number of warrants outstanding as of June 30, 2023: Number of warrants Weighted average exercise price Thousands Balance, December 31, 2022 961 $ 24.84 Exercised (1 ) 8.00 Balance, June 30, 2023 960 $ 24.84 Date of expiry Warrants outstanding Exercise price Grant date fair value Remaining life in years Thousands November 18, 2026 221 $ 75.00 $ 6,700 3.39 November 18, 2026 66 8.00 422 3.39 November 18, 2027 23 66.00 1,055 4.39 December 8, 2027 625 8.00 2,033 4.44 December 8, 2027 25 8.80 149 4.44 960 $ 24.84 $ 10,359 4.13

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES [Text Block]	16. COMMITMENTS AND CONTINGENCIES Provisions The Company's current known provisions and contingent liabilities consist of the following as of June 30, 2023: Termination benefits Legal disputes Sales tax Total Balance as at December 31, 2022 $ 183 $ 3,030 $ 1,831 $ 5,044 Payments/Settlements (183 ) (98 ) - (281 ) Additional provisions - - 389 389 Foreign currency translation - 36 - 36 Balance as at June 30, 2023 $ - $ 2,968 $ 2,220 $ 5,188 The legal disputes balance as of June 30, 2023 involves a former shareholder of ACA Muller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly owned subsidiary of the Company in the Constance Regional Court in Germany. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $3.0 million. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $3.0 million to reflect the value of the claim. This dispute is covered under the indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH as discussed in Note 8. The Company intends to vigorously defend itself through appropriate legal proceedings. The $3.0 million is recorded within contingencies and within indemnification receivables on the unaudited condensed interim consolidated statements of financial. The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The ending balance is recorded within contingencies on the unaudited condensed interim consolidated statement of financial position, and additions to the provision as a reduction of revenue on the unaudited condensed interim consolidated statements of loss and comprehensive loss. Legal proceedings The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at June 30, 2023. On June 21, 2022, an action was brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company is obligated to issue 3.0 million (pre-one-for three reverse stock split) common shares to him for a purchase price of $0.05 per share. Mr. Mendez claims he is entitled to such shares as a result of alleged consulting services he performed in 2019. The Company disputes his claims and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of June 30, 2023. In connection with the Company's acquisition of FGH, the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof: On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, 8,831,109 FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties by Mr. Starke. FGH has been named as a defendant by virtue of the alleged wrongful conduct by Mr. Starke. The plaintiffs are seeking damages of $3.9 million. The defendants have all brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement. The total amount claimed against the former entities of FGH currently exceeds the maximum $5.0 million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $5.0 million.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
LOSS PER SHARE	Jun. 30, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE [Text Block]	17. LOSS PER SHARE The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive as the Company has a net loss for each period presented: June 30, 2023 December 31, 2022 Stock options 220 290 Warrants 960 961 Restricted stock awards 65 146 JustCBD potential additional shares to settle contingent consideration 657 657 Total anti-dilutive 1,902 2,054

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	6 Months Ended
FINANCIAL INSTRUMENTS	Jun. 30, 2023
Financial Instruments [Abstract]
FINANCIAL INSTRUMENTS [Text Block]	18. FINANCIAL INSTRUMENTS Fair value The Company's financial instruments measured at amortized cost as at June 30, 2023 and December 31, 2022 consist of cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the unaudited condensed interim consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments. Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on: Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and Level 3 - inputs for the instruments are not based on any observable market data. The Company's long-term investments require significant unobservable inputs and as discussed at Note 7, are measured at FVPL and as a Level 3 fair value financial instrument within the fair value hierarchy as at June 30, 2023. As discussed in Note 8, the Company's contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022, NoCap in July 2022 and Original Hemp in March 2023. The amount is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at June 30, 2023. As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company's financial condition or operating results. The following tables present information about the Company's financial instruments and their classifications as at June 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. Fair value measurements at June 30, 2023 using: Level 1 Level 2 Level 3 Total Financial assets: Investments (Note 7) $ - $ - $ 200 $ 200 Financial liabilities: Contingent purchase consideration from asset acquisitions and business combinations (Note 8) $ - $ 2,354 $ - $ 2,354 Fair value measurements at December 31, 2022 using: Level 1 Level 2 Level 3 Total Financial assets: Investments (Note 7) $ - $ - $ 734 $ 734 Financial liabilities: Contingent purchase consideration from business combinations (Note 8) $ - $ 3,547 $ - $ 3,547

SEGMENTED INFORMATION

SEGMENTED INFORMATION	6 Months Ended
SEGMENTED INFORMATION	Jun. 30, 2023
Segment Reporting [Abstract]
SEGMENTED INFORMATION [Text Block]	19. SEGMENTED INFORMATION The Company reports its financial results for the following three operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH and Cosechemos subsidiaries), house of brands (primarily JustCBD, Vessel and Kasa Wholefoods Company subsidiaries), and pharmaceuticals (primarily Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's operates its manufacturing and distribution business in its United States, Germany, and Colombia subsidiaries. The Company also was engaged in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products through its Colombia Cosechemos subsidiary. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations. Information regarding the Company's segments is summarized as follows: For the three months ended For the three months ended For the six months ended For the six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net Sales Commercial & Wholesale $ 10,797 $ - $ 18,755 $ - House of Brands 13,000 10,810 26,765 15,793 Pharmaceuticals - - - - Eliminations (2,337 ) (1,867 ) (4,741 ) (2,649 ) $ 21,460 $ 8,943 $ 40,779 $ 13,144 Net Loss Commercial & Wholesale $ (6,710 ) $ - $ (6,737 ) $ - House of Brands (28,763 ) (17,354 ) (29,118 ) (18,016 ) Pharmaceuticals (36 ) - (81 ) - Corp & Eliminations (1,482 ) (5,698 ) (4,242 ) (11,291 ) $ (36,991 ) $ (23,052 ) $ (40,178 ) $ (29,307 ) As at June 30, 2023 December 31, 2022 Assets Commercial & Wholesale $ 11,129 $ 22,225 House of Brands 16,317 48,950 Pharmaceuticals 1,159 3,313 Corp & Eliminations 1,874 6,499 $ 30,479 $ 80,987 Disaggregation of net sales by geographic area: For the three months ended For the three months ended For the six months ended For the six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net Sales United States $ 10,352 $ 8,679 $ 21,351 $ 12,745 Germany 10,797 - 18,755 - United Kingdom 311 264 673 399 $ 21,460 $ 8,943 $ 40,779 $ 13,144

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS [Text Block]	20. SUBSEQUENT EVENTS SALE OF COLOMBIA ENTITIES On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million). The Company sold all of its shares and assets related to the following Colombian companies and branches: Flora Growth Corp Colombia S.A.S. (formerly Hemp Textiles & Co. S.A.S.) Flora Lab S.A.S. (formerly Grupo Farmaceutico Cronomed S.A.S.) Flora Med S.A.S. (formerly Breeze Laboratory S.A.S.) Labcofarm Laboratorios S.A.S Cosechemos Ya S.A.S. Kasa Wholefoods Company S.A.S. Flora Growth Corp. Sucursal Colombia Flora Beauty LLC Sucursal Colombia The applicable capital stock of the Colombian entities will be transferred to Lisan at the date of closing. All assets underlying this sale are expected to be transferred to Lisan on an "as is where is" basis within the next 30 days. See discussion in Note 3. OTHER Subsequent to June 30, 2023, a total of 4,000 restricted shares were forfeited and a total of 51,432 options were forfeited.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
BASIS OF PRESENTATION (Policies)	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going concern [Policy Text Block]	Going concern The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash of $1.8 million at June 30, 2023, net loss of $48.5 million for the six months ended June 30, 2023, and an accumulated deficit of $138.3 million at June 30, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these interim condensed consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Basis of consolidation [Policy Text Block]	Basis of consolidation These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. The Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2022. On July 5, 2023, the Company sold its shares in its Colombian related subsidiaries. The results of these subsidiaries are included in discontinued operations in the accompanying unaudited condensed interim consolidated financial statements. See discussion in Note 3.

ASSETS HELD FOR SALE AND DISC_2

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)	6 Months Ended
ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of major classes of assets and liabilities held for sale [Table Text Block]	June 30, 2023 December 31, 2022 Assets held for sale Cash $ 448 $ 602 Trade and amounts receivable 633 1,592 Prepaid expenses and other current assets 115 174 Inventory 582 1,341 Total current assets held for sale 1,778 3,709 Property, plant and equipment - 3,592 Operating lease right of use assets - 419 Intangible assets - 358 Other assets - 23 Total noncurrent assets held for sale - 4,392 Total assets held for sale $ 1,778 $ 8,101 Liabilities held for sale Current portion of long-term debt $ 38 $ - Current portion of operating lease liability 370 72 Other accrued liabilities 767 538 Total current liabilities held for sale 1,175 610 Non-current operating lease liability - 308 Total liabilities held for sale $ 1,175 $ 918
Schedule of loss from discontinued operations [Table Text Block]	For the three For the three For the six For the six Revenue $ 662 $ 1,028 $ 1,450 $ 1,773 Cost of sales 466 471 1,123 774 Gross profit from discontinued operations 196 557 327 999 Consulting and management fees 307 683 676 1,267 Professional fees 46 120 82 391 General and administrative 105 419 282 769 Promotion and communication 8 131 14 305 Operating lease expense 43 106 93 122 Depreciation and amortization 70 186 148 296 Bad debt expense 565 150 565 150 Asset impairment 4,704 - 4,704 - Other (income) expense 2 363 124 666 Operating loss from discontinued operations (5,654 ) (1,601 ) (6,361 ) (2,967 ) Interest (income) expense 2 19 2 28 Net loss before income taxes (5,656 ) (1,620 ) (6,363 ) (2,995 ) Loss on disposal of discontinued operations 1,909 - 1,909 - Income tax expense - - 11 - Loss from discontinued operations $ (7,565 ) $ (1,620 ) $ (8,283 ) $ (2,995 )
Schedule of significant operating and investing items [Table Text Block]	For the six For the six Operating activities of discontinued operations Depreciation and amortization $ 148 $ 296 Bad debt expense 565 150 Asset impairment 4,704 - Investing activities of discontinued operations Purchases of property, plant and equipment $ 92 $ 579

TRADE AND AMOUNTS RECEIVABLE (T

TRADE AND AMOUNTS RECEIVABLE (Tables)	6 Months Ended
TRADE AND AMOUNTS RECEIVABLE (Tables)	Jun. 30, 2023
Trade And Other Receivables [Abstract]
Schedule of trade and amounts receivable [Table Text Block]	June 30, 2023 December 31, 2022 Trade accounts receivable $ 3,894 $ 4,288 Allowance for expected credit losses (1,346 ) (1,385 ) HST/VAT receivable 2,126 2,294 Other receivables 180 62 Total $ 4,854 $ 5,259
Schedule of aging of trade accounts receivable [Table Text Block]	June 30, 2023 Current $ 672 1-30 Days 924 31-60 Days 432 61-90 Days 197 91-180 Days 570 180+ Days 1,099 Total trade receivables $ 3,894

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
INVENTORY (Tables)	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of inventory [Table Text Block]	June 30, 2023 December 31, 2022 Raw materials and supplies $ 1,669 $ 2,363 Finished goods 7,015 6,384 Total $ 8,684 $ 8,747

PROPERTY PLANT AND EQUIPMENT (T

PROPERTY PLANT AND EQUIPMENT (Tables)	6 Months Ended
PROPERTY PLANT AND EQUIPMENT (Tables)	Jun. 30, 2023
PROPERTY PLANT AND EQUIPMENT
Schedule of property, plant and equipment [Table Text Block]	June 30, 2023 December 31, 2022 Land $ 296 $ 291 Buildings - - Machinery and office equipment 759 1,098 Vehicles 81 37 Total 1,136 1,426 Less: accumulated depreciation (185 ) (208 ) Property, plant and equipment, net $ 951 $ 1,218

INVESTMENTS (Tables)

INVESTMENTS (Tables)	6 Months Ended
INVESTMENTS (Tables)	Jun. 30, 2023
INVESTMENTS
Schedule of investments activity [Table Text Block]	Investee common shares Warrants CAD 0.30 exercise price Warrants CAD 1.00 exercise price Total Financial asset hierarchy level Level 3 Level 3 Level 3 Balance at December 31, 2022 $ 730 $ 34 $ - $ 764 Loss on changes in fair value (530 ) (34 ) - (564 ) Balance at June 30, 2023 $ 200 $ - $ - $ 200

ASSET ACQUISITIONS AND BUSINE_2

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)	6 Months Ended
ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)	Jun. 30, 2023
Original Hemp asset acquisition [Member]
Business Acquisition [Line Items]
Schedule of major class of assets acquired and liabilities [Table Text Block]	Inventory $ 109 Intangible asset 194 Total net assets acquired $ 303
Franchise Global Health Inc [Member]
Business Acquisition [Line Items]
Schedule of major class of assets acquired and liabilities [Table Text Block]	Current assets Cash $ 730 Trade receivables 2,271 Inventory 2,019 Indemnity receivables 3,415 Prepaid assets 139 Non-current assets Property, plant, and equipment 452 Right of use assets 115 Intangible asset 6,102 Goodwill 3,716 Total assets $ 18,959 Current liabilities Trade payables and accrued liabilities $ (6,245 ) Current lease liabilities (98 ) Current portion of debt (1,062 ) Long term lease liability (21 ) Deferred tax (1,717 ) Total liabilities $ (9,143 ) Total net assets acquired $ 9,816
Just Brands LLC and High Roller Private Label LLC [Member]
Business Acquisition [Line Items]
Schedule of major class of assets acquired and liabilities [Table Text Block]	Current assets Cash $ 535 Trade receivables 975 Inventory 5,534 Other current assets 540 Non-current assets Property, plant, and equipment 536 Right of use assets 772 Other non-current assets 127 Intangible asset 4,533 Goodwill 24,898 Total assets $ 38,450 Current liabilities Trade payables and accrued liabilities $ (2,273 ) Current lease liabilities (644 ) Provision for sales tax (982 ) Deferred tax (24 ) Other current liabilities (99 ) Total liabilities $ (4,022 ) Total net assets acquired $ 34,428
No Cap Hemp Co [Member]
Business Acquisition [Line Items]
Schedule of major class of assets acquired and liabilities [Table Text Block]	Current assets Trade receivables $ 31 Inventory 725 Non-current assets Goodwill 417 Total assets $ 1,173 Current liabilities Trade payables and accrued liabilities (272 ) Total liabilities $ (272 ) Total net assets acquired $ 901

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	6 Months Ended
INTANGIBLE ASSETS AND GOODWILL (Tables)	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets [Table Text Block]	License Customer/Supplier Relationships Trademarks Patents Non- Goodwill Total Cost At December 31, 2022 $ 1,396 $ 7,512 $ 5,154 $ 4,530 $ 1,190 $ 23,633 $ 43,415 Additions - 194 - - - - 194 Impairment (752 ) (4,418 ) (1,599 ) (3,432 ) (529 ) (23,372 ) (34,102 ) At June 30, 2023 $ 644 $ 3,288 $ 3,555 $ 1,098 $ 661 $ 261 $ 9,507 Accumulated Amortization At December 31, 2022 $ - $ 348 $ 618 $ 621 $ 463 $ - $ 2,050 Additions 142 663 319 277 198 - 1,599 At June 30, 2023 $ 142 $ 1,011 $ 937 $ 898 $ 661 $ - $ 3,649 Foreign currency translation 24 76 20 - - (261 ) (141 ) Net book value at June 30, 2023 $ 526 $ 2,353 $ 2,638 $ 200 $ - $ - $ 5,717
Schedule of estimation of amortization expense [Table Text Block]	2023 $ 587 2024 1,173 2025 1,109 2026 1,096 2027 1,032 Thereafter 720 Total $ 5,717
Schedule of goodwill [Table Text Block]	Vessel JustCBD Franchise Total Gross goodwill recorded prior to December 31, 2022 $ 19,675 $ 25,038 $ 3,732 $ 48,445 Impairment recorded prior to December 31, 2022 (19,675 ) (5,398 ) - (25,073 ) Net book value as at December 31, 2022 - 19,640 3,732 23,372 Impairment recorded - (19,640 ) (3,732 ) (23,372 ) Net book value as at June 30, 2023 $ - $ - $ - $ -

LEASES (Tables)

LEASES (Tables)	6 Months Ended
LEASES (Tables)	Jun. 30, 2023
Leases [Abstract]
Schedule of leases [Table Text Block]	Three months ended June 30, 2023 Three months ended June 30, 2022 Six months ended June 30, 2023 Six months ended June 30, 2022 Components of lease expense Operating lease expense $ 308 $ 136 $ 624 $ 327 Short-term lease expense 62 82 135 233 Total lease expense $ 370 $ 218 $ 759 $ 560 Other Information Operating cash flows from operating leases $ 356 $ 216 $ 720 $ 489 ROU assets obtained in exchange for new operating lease liabilities - 2,097 97 2,825 Weighted-average remaining lease term in years for operating leases 3.4 4.5 Weighted-average discount rate for operating leases 7.7% 8.1%
Schedule of maturities of operating lease liabilities [Table Text Block]	Thousands of United States dollars Operating Leases 2023 $ 1,234 2024 425 2025 396 2026 321 2027 48 Total future lease payments 2,424 Less: imputed interest (247 ) Total lease liabilities 2,177 Less: current lease liabilities (1,124 ) Total non-current lease liabilities $ 1,053

SHARE BASED COMPENSATION (Table

SHARE BASED COMPENSATION (Tables)	6 Months Ended
SHARE BASED COMPENSATION (Tables)	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of share options outstanding and exercisable [Table Text Block]	Options Outstanding Number of Weighted Weighted average Aggregate Outstanding balance, December 31, 2022 290 $ 34.17 4.2 $ 64 Granted 5 $ 7.00 9.7 - Cancelled (75 ) $ 24.75 6.0 - Outstanding balance, June 30, 2023 220 $ 36.79 3.0 $ - Exercisable balance, June 30, 2023 203 $ 38.86 2.6 $ -
Schedule of restricted stock awards [Table Text Block]	Number of Weighted Thousands Balance, December 31, 2022 146 $ 13.64 Granted 112 5.85 Vested (38 ) (13.74 ) Cancelled (155 ) (9.17 ) Balance, June 30, 2023 65 $ 11.22

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
WARRANTS (Tables)	Jun. 30, 2023
Warrants [Abstract]
Schedule of warrants outstanding [Table Text Block]	Number of warrants Weighted average exercise price Thousands Balance, December 31, 2022 961 $ 24.84 Exercised (1 ) 8.00 Balance, June 30, 2023 960 $ 24.84
Schedule of warrants outstanding by date of expiry [Table Text Block]	Date of expiry Warrants outstanding Exercise price Grant date fair value Remaining life in years Thousands November 18, 2026 221 $ 75.00 $ 6,700 3.39 November 18, 2026 66 8.00 422 3.39 November 18, 2027 23 66.00 1,055 4.39 December 8, 2027 625 8.00 2,033 4.44 December 8, 2027 25 8.80 149 4.44 960 $ 24.84 $ 10,359 4.13

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of provisions and contingent liabilities [Table Text Block]	Termination benefits Legal disputes Sales tax Total Balance as at December 31, 2022 $ 183 $ 3,030 $ 1,831 $ 5,044 Payments/Settlements (183 ) (98 ) - (281 ) Additional provisions - - 389 389 Foreign currency translation - 36 - 36 Balance as at June 30, 2023 $ - $ 2,968 $ 2,220 $ 5,188

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
LOSS PER SHARE (Tables)	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of anti-dilutive shares [Table Text Block]	June 30, 2023 December 31, 2022 Stock options 220 290 Warrants 960 961 Restricted stock awards 65 146 JustCBD potential additional shares to settle contingent consideration 657 657 Total anti-dilutive 1,902 2,054

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
FINANCIAL INSTRUMENTS (Tables)	Jun. 30, 2023
Financial Instruments [Abstract]
Schedule of information about the financial instruments and their classifications [Table Text Block]	Fair value measurements at June 30, 2023 using: Level 1 Level 2 Level 3 Total Financial assets: Investments (Note 7) $ - $ - $ 200 $ 200 Financial liabilities: Contingent purchase consideration from asset acquisitions and business combinations (Note 8) $ - $ 2,354 $ - $ 2,354 Fair value measurements at December 31, 2022 using: Level 1 Level 2 Level 3 Total Financial assets: Investments (Note 7) $ - $ - $ 734 $ 734 Financial liabilities: Contingent purchase consideration from business combinations (Note 8) $ - $ 3,547 $ - $ 3,547

SEGMENTED INFORMATION (Tables)

SEGMENTED INFORMATION (Tables)	6 Months Ended
SEGMENTED INFORMATION (Tables)	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of operation segment information [Table Text Block]	For the three months ended For the three months ended For the six months ended For the six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net Sales Commercial & Wholesale $ 10,797 $ - $ 18,755 $ - House of Brands 13,000 10,810 26,765 15,793 Pharmaceuticals - - - - Eliminations (2,337 ) (1,867 ) (4,741 ) (2,649 ) $ 21,460 $ 8,943 $ 40,779 $ 13,144 Net Loss Commercial & Wholesale $ (6,710 ) $ - $ (6,737 ) $ - House of Brands (28,763 ) (17,354 ) (29,118 ) (18,016 ) Pharmaceuticals (36 ) - (81 ) - Corp & Eliminations (1,482 ) (5,698 ) (4,242 ) (11,291 ) $ (36,991 ) $ (23,052 ) $ (40,178 ) $ (29,307 ) As at June 30, 2023 December 31, 2022 Assets Commercial & Wholesale $ 11,129 $ 22,225 House of Brands 16,317 48,950 Pharmaceuticals 1,159 3,313 Corp & Eliminations 1,874 6,499 $ 30,479 $ 80,987
Schedule of disaggregation of net sales by geographic area [Table Text Block]	For the three months ended For the three months ended For the six months ended For the six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net Sales United States $ 10,352 $ 8,679 $ 21,351 $ 12,745 Germany 10,797 - 18,755 - United Kingdom 311 264 673 399 $ 21,460 $ 8,943 $ 40,779 $ 13,144

BASIS OF PRESENTATION (Narrativ

BASIS OF PRESENTATION (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,800		$ 1,800
Net loss	(44,556)	$ (24,672)	(48,461)	$ (32,302)
Accumulated deficit	$ (138,300)		$ (138,300)

ASSETS HELD FOR SALE AND DISC_3

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details) $ in Millions, $ in Millions				3 Months Ended	6 Months Ended
	Aug. 03, 2023 CAD ($)	Jul. 05, 2023 CAD ($)	Jul. 05, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal of discontinued operations				$ 1.9	$ 1.9
Subsequent Event [Member] \| Share Purchase Agreement [Member] \| Lisan Farma Colombia LLC [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price	$ 0.5	$ 0.8	$ 0.6

ASSETS HELD FOR SALE AND DISC_4

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Assets held for sale
Cash	$ 448		$ 381
Discontinued Operations, Held-for-Sale [Member] \| Share Purchase Agreement [Member] \| Lisan Farma Colombia LLC [Member] \| Colombian related subsidiaries and Colombian assets [Member]
Assets held for sale
Cash	448	$ 602
Trade and amounts receivable	633	1,592
Prepaid expenses and other current assets	115	174
Inventory	582	1,341
Total current assets held for sale	1,778	3,709
Property, plant and equipment	0	3,592
Operating lease right of use assets	0	419
Intangible assets	0	358
Other assets	0	23
Total noncurrent assets held for sale	0	4,392
Total assets held for sale	1,778	8,101
Liabilities held for sale
Current portion of long-term debt	38	0
Current portion of operating lease liability	370	72
Other accrued liabilities	767	538
Total current liabilities held for sale	1,175	610
Non-current operating lease liability	0	308
Total liabilities held for sale	$ 1,175	$ 918

ASSETS HELD FOR SALE AND DISC_5

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal of discontinued operations	$ 1,900		$ 1,900
Loss from discontinued operations	(7,565)	$ (1,620)	(8,283)	$ (2,995)
Discontinued Operations, Held-for-Sale [Member] \| Share Purchase Agreement [Member] \| Lisan Farma Colombia LLC [Member] \| Colombian related subsidiaries and Colombian assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	662	1,028	1,450	1,773
Cost of sales	466	471	1,123	774
Gross profit from discontinued operations	196	557	327	999
Consulting and management fees	307	683	676	1,267
Professional fees	46	120	82	391
General and administrative	105	419	282	769
Promotion and communication	8	131	14	305
Operating lease expense	43	106	93	122
Depreciation and amortization	70	186	148	296
Bad debt expense	565	150	565	150
Asset impairment	4,704	0	4,704	0
Other (income) expense	2	363	124	666
Operating loss from discontinued operations	(5,654)	(1,601)	(6,361)	(2,967)
Interest (income) expense	2	19	2	28
Net loss before income taxes	(5,656)	(1,620)	(6,363)	(2,995)
Loss on disposal of discontinued operations	1,909	0	1,909	0
Income tax expense	0	0	11	0
Loss from discontinued operations	$ (7,565)	$ (1,620)	$ (8,283)	$ (2,995)

ASSETS HELD FOR SALE AND DISC_6

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details) - Discontinued Operations, Held-for-Sale [Member] - Share Purchase Agreement [Member] - Lisan Farma Colombia Llc [Member] - Colombian related subsidiaries and Colombian assets [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating Activities Of Discontinued Operations [Abstract]
Depreciation and amortization			$ 148	$ 296
Bad debt expense	$ 565	$ 150	565	150
Asset impairment	$ 4,704	$ 0	4,704	0
Investing Activities Of Discontinued Operations [Abstract]
Purchases of property, plant and equipment			$ 92	$ 579

TRADE AND AMOUNTS RECEIVABLE (N

TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Trade And Other Receivables [Abstract]
Write-offs of trade receivables	$ 0.1	$ 0.1

TRADE AND AMOUNTS RECEIVABLE (S

TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade And Other Receivables [Abstract]
Trade accounts receivable	$ 3,894	$ 4,288
Allowance for expected credit losses	(1,346)	(1,385)
HST/VAT receivable	2,126	2,294
Other receivables	180	62
Total	$ 4,854	$ 5,259

TRADE AND AMOUNTS RECEIVABLE _2

TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Total trade receivables	$ 3,894	$ 4,288
Current [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	672
1-30 Days [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	924
31-60 Days [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	432
61-90 Days [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	197
91-180 Days [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	570
180+ Days [Member]
Financing Receivable, Past Due [Line Items]
Total trade receivables	$ 1,099

INVENTORY (Schedule of inventor

INVENTORY (Schedule of inventory) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,669	$ 2,363
Finished goods	7,015	6,384
Total	$ 8,684	$ 8,747

PROPERTY PLANT AND EQUIPMENT (N

PROPERTY PLANT AND EQUIPMENT (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
PROPERTY PLANT AND EQUIPMENT
Depreciation expense	$ 0.1	$ 0.1	$ 0.1	$ 0.1
Impairment of property plant and equipment	$ 0.2		$ 0.2

PROPERTY PLANT AND EQUIPMENT (S

PROPERTY PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 1,136	$ 1,426
Less: accumulated depreciation	(185)	(208)
Property, plant and equipment, net	951	1,218
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	296	291
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	0	0
Machinery and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	759	1,098
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 81	$ 37

INVESTMENTS (Narrative) (Detail

INVESTMENTS (Narrative) (Details) $ in Millions	6 Months Ended
INVESTMENTS (Narrative) (Details) $ in Millions	Jun. 30, 2023 USD ($)
INVESTMENTS
Investment description	The Company owned approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of other investors.
Description of impairment	The initial investment multiples were compared to the guideline public company multiples observed as at June 30, 2023 (0.4 price to book value and 0.5 price to tangible value), with these updated valuation multiples applied to the investee's estimated book value.
Impairment of investment	$ 0.5

INVESTMENTS (Schedule of invest

INVESTMENTS (Schedule of investments activity) (Details) - Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Investments in and Advances to Affiliates, Activity [Line Items]
Investments, Beginning Balance	$ 764
Loss on changes in fair value	(564)
Investments, Ending Balance	200
Investee Common Shares [Member]
Investments in and Advances to Affiliates, Activity [Line Items]
Investments, Beginning Balance	730
Loss on changes in fair value	(530)
Investments, Ending Balance	200
Warrants CAD 0.30 [Member]
Investments in and Advances to Affiliates, Activity [Line Items]
Investments, Beginning Balance	34
Loss on changes in fair value	(34)
Investments, Ending Balance	0
Warrants CAD 1.00 [Member]
Investments in and Advances to Affiliates, Activity [Line Items]
Investments, Beginning Balance	0
Loss on changes in fair value	0
Investments, Ending Balance	$ 0

ASSET ACQUISITIONS AND BUSINE_3

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended		6 Months Ended
	Mar. 01, 2023 USD ($)	Dec. 23, 2022 USD ($) shares	Jul. 20, 2022 USD ($)	Feb. 24, 2022 USD ($) Trials $ / shares shares	Jun. 30, 2023 USD ($) $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Trials $ / shares	Jun. 30, 2022 USD ($)
Business Acquisition [Line Items]
Share based compensation					$ 338	$ 1,263	$ 992	$ 2,789
Original Hemp asset acquisition [Member]
Business Acquisition [Line Items]
Purchase consideration	$ 300
Amount payable of net profits	50%
Cash paid	$ 200
Amount payable of profits for additional amount	10%
Additional paid amount	$ 400
Maximum payment accumulated for valuation	600
Acquisition fair value	300
Outstanding balance					$ 300		$ 300
Intangible asset	$ 194
Original Hemp asset acquisition [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Discount rate	17%
Original Hemp asset acquisition [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Discount rate	31.50%
Franchise Global Health Inc. ("FGH") business combination [Member]
Business Acquisition [Line Items]
Common shares in purchase consideration \| shares		2,176,297
Purchase consideration, Total		$ 9,800
Fair value discount		7.50%
Trade payables and accrued liabilities		$ 3,400
Indemnification receivables		3,400
Intangible asset		6,102
Franchise Global Health Inc. ("FGH") business combination [Member] \| Supplier Relationships [Member]
Business Acquisition [Line Items]
Intangible asset		2,400
Franchise Global Health Inc. ("FGH") business combination [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible asset		2,300
Franchise Global Health Inc. ("FGH") business combination [Member] \| Licenses [Member]
Business Acquisition [Line Items]
Intangible asset		1,400
Franchise Global Health Inc. ("FGH") business combination [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Liabilities		$ 5,000
Just Brands LLC and High Roller Private Label LLC business combination [Member]
Business Acquisition [Line Items]
Purchase consideration				$ 4,000
Share based compensation				$ 37,000
Net asset acquired				100%
Cash				$ 16,000
Working capital				$ 200
Number of common shares in purchase consideration \| shares				475,000
Value of common shares in purchase consideration				$ 14,700
Fair value discount				15%
Weighted average price \| $ / shares				$ 100
Additional common shares				$ 47,500
Common shares delivered to sellers \| shares				475,000
Description of shares				Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500 shares
Number of trials \| Trials				100,000			100,000
Closing share price \| $ / shares				$ 36.4	$ 2.38		$ 2.38
Common share volatility				100%			110%
Risk-free interest rate				1.50%			5.50%
Contingent consideration							$ 1,500
Unrealized losses on securities							1,100
Discount				$ 300
Intangible asset				4,533
Just Brands LLC and High Roller Private Label LLC business combination [Member] \| Tradename [Member]
Business Acquisition [Line Items]
Intangible asset				3,100
Just Brands LLC and High Roller Private Label LLC business combination [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible asset				1,200
Just Brands LLC and High Roller Private Label LLC business combination [Member] \| Know-how [Member]
Business Acquisition [Line Items]
Intangible asset				$ 200
No Cap Hemp Co [Member]
Business Acquisition [Line Items]
Share based compensation			$ 900
Equity interests own			10%
Breeze vendors payment			$ 2,000
Contingent consideration							500
Unrealized losses on securities							$ 400
Discount			200
Advanced payable			$ 200
Description of discount rates			the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million
No Cap Hemp Co [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Discount rate			14.30%
No Cap Hemp Co [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Discount rate			23.50%

ASSET ACQUISITIONS AND BUSINE_4

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 01, 2023	Dec. 31, 2022	Dec. 23, 2022	Jul. 20, 2022	Feb. 24, 2022
Non-current assets
Goodwill	$ 0		$ 23,372
Original Hemp asset acquisition [Member]
Current assets
Inventory		$ 109
Non-current assets
Intangible asset		194
Current liabilities
Total net assets acquired		$ 303
Franchise Global Health Inc. ("FGH") business combination [Member]
Current assets
Cash				$ 730
Trade receivables				2,271
Inventory				2,019
Indemnity receivables				3,415
Prepaid assets				139
Non-current assets
Property, plant, and equipment				452
Right of use assets				115
Intangible asset				6,102
Goodwill				3,716
Total assets				18,959
Current liabilities
Trade payables and accrued liabilities				(6,245)
Current lease liabilities				(98)
Current portion of debt				(1,062)
Long term lease liability				(21)
Deferred Tax				(1,717)
Total liabilities				(9,143)
Total net assets acquired				$ 9,816
Just Brands LLC and High Roller Private Label LLC business combination [Member]
Current assets
Cash						$ 535
Trade receivables						975
Inventory						5,534
Other current assets						540
Non-current assets
Property, plant, and equipment						536
Right of use assets						772
Other non-current assets						127
Intangible asset						4,533
Goodwill						24,898
Total assets						38,450
Current liabilities
Trade payables and accrued liabilities						(2,273)
Current lease liabilities						(644)
Provision for sales tax						(982)
Deferred Tax						(24)
Other current liabilities						(99)
Total liabilities						(4,022)
Total net assets acquired						$ 34,428
No Cap Hemp Co. business combination [Member]
Current assets
Trade receivables					$ 31
Inventory					725
Non-current assets
Goodwill					417
Total assets					1,173
Current liabilities
Trade payables and accrued liabilities					(272)
Total liabilities					(272)
Total net assets acquired					$ 901

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 800	$ 300	$ 1,599	$ 900
Weighted average amortization period remaining for intangible assets	5 years 8 months 12 days		5 years 8 months 12 days

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			$ 43,415
Intangible assets, Cost, Additions			194
Intangible assets, Cost, Impairment			(34,102)
Intangible assets, Cost, Ending balance	$ 9,507		9,507
Intangible assets, Accumulated Amortization, Beginning balance			2,050
Intangible assets, Accumulated Amortization, Additions	800	$ 300	1,599	$ 900
Intangible assets, Accumulated Amortization, Ending balance	3,649		3,649
Intangible assets, Foreign Currency translation			(141)
Intangible assets, Net book value, Ending balance	5,717		5,717
License [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			1,396
Intangible assets, Cost, Additions			0
Intangible assets, Cost, Impairment			(752)
Intangible assets, Cost, Ending balance	644		644
Intangible assets, Accumulated Amortization, Beginning balance			0
Intangible assets, Accumulated Amortization, Additions			142
Intangible assets, Accumulated Amortization, Ending balance	142		142
Intangible assets, Foreign Currency translation			24
Intangible assets, Net book value, Ending balance	526		526
Customer/Supplier Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			7,512
Intangible assets, Cost, Additions			194
Intangible assets, Cost, Impairment			(4,418)
Intangible assets, Cost, Ending balance	3,288		3,288
Intangible assets, Accumulated Amortization, Beginning balance			348
Intangible assets, Accumulated Amortization, Additions			663
Intangible assets, Accumulated Amortization, Ending balance	1,011		1,011
Intangible assets, Foreign Currency translation			76
Intangible assets, Net book value, Ending balance	2,353		2,353
Trademarks and Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			5,154
Intangible assets, Cost, Additions			0
Intangible assets, Cost, Impairment			(1,599)
Intangible assets, Cost, Ending balance	3,555		3,555
Intangible assets, Accumulated Amortization, Beginning balance			618
Intangible assets, Accumulated Amortization, Additions			319
Intangible assets, Accumulated Amortization, Ending balance	937		937
Intangible assets, Foreign Currency translation			20
Intangible assets, Net book value, Ending balance	2,638		2,638
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			4,530
Intangible assets, Cost, Additions			0
Intangible assets, Cost, Impairment			(3,432)
Intangible assets, Cost, Ending balance	1,098		1,098
Intangible assets, Accumulated Amortization, Beginning balance			621
Intangible assets, Accumulated Amortization, Additions			277
Intangible assets, Accumulated Amortization, Ending balance	898		898
Intangible assets, Foreign Currency translation			0
Intangible assets, Net book value, Ending balance	200		200
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			1,190
Intangible assets, Cost, Additions			0
Intangible assets, Cost, Impairment			(529)
Intangible assets, Cost, Ending balance	661		661
Intangible assets, Accumulated Amortization, Beginning balance			463
Intangible assets, Accumulated Amortization, Additions			198
Intangible assets, Accumulated Amortization, Ending balance	661		661
Intangible assets, Foreign Currency translation			0
Intangible assets, Net book value, Ending balance	0		0
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost, Beginning balance			23,633
Intangible assets, Cost, Additions			0
Intangible assets, Cost, Impairment			(23,372)
Intangible assets, Cost, Ending balance	261		261
Intangible assets, Accumulated Amortization, Beginning balance			0
Intangible assets, Accumulated Amortization, Additions			0
Intangible assets, Accumulated Amortization, Ending balance	0		0
Intangible assets, Foreign Currency translation			(261)
Intangible assets, Net book value, Ending balance	$ 0		$ 0

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 587
2024	1,173
2025	1,109
2026	1,096
2027	1,032
Thereafter	720
Finite-Lived Intangible Assets, Net, Total	$ 5,717

INTANGIBLE ASSETS AND GOODWIL_5

INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill [Line Items]
Gross goodwill		$ 48,445
Impairment recorded	$ (23,372)	(25,073)
Net book value	0	23,372
Vessel [Member]
Goodwill [Line Items]
Gross goodwill		19,675
Impairment recorded	0	(19,675)
Net book value	0	0
JustCBD [Member]
Goodwill [Line Items]
Gross goodwill		25,038
Impairment recorded	(19,640)	(5,398)
Net book value	0	19,640
Franchise [Member]
Goodwill [Line Items]
Gross goodwill		3,732
Impairment recorded	(3,732)	0
Net book value	$ 0	$ 3,732

IMPAIRMENT OF ASSETS (Narrative

IMPAIRMENT OF ASSETS (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill [Line Items]
Impairments	$ 34,941	$ 15,652	$ 34,941	$ 15,652
JustCBD [Member] \| Goodwill [Member]
Goodwill [Line Items]
Goodwill impairment			19,600
Fair value of reporting unit	7,800		$ 7,800
Income approach, operating margins, description			The income approach used a discount rate of 32%, operating margins from 3% to 9%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and drop down to 3% in 2024 and thereafter.
JustCBD [Member] \| House of Brands Segment [Member]
Goodwill [Line Items]
Impairments			$ 400
FGH [Member] \| Goodwill [Member]
Goodwill [Line Items]
Goodwill impairment			3,700
Fair value of reporting unit	$ 2,300		$ 2,300
Income approach, operating margins, description			The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter.
FGH [Member] \| Commercial and Wholesale Segment [Member]
Goodwill [Line Items]
Impairments			$ 3,700
Vessel Asset Group [Member] \| House of Brands Segment [Member]
Goodwill [Line Items]
Impairments			$ 6,600

DEBT (Narrative) (Details)

DEBT (Narrative) (Details) € in Millions, $ in Millions	6 Months Ended
DEBT (Narrative) (Details) € in Millions, $ in Millions	Jun. 30, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Hypoverinsbank [Member] \| Euro Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility \| €	€ 1
Outstanding amount	€ 1	$ 1.1
Line of credit facility, interest rate description	The credit facility has a rate of Euro Interbank Offer Rate ("Euribor") plus 2.95% per year	The credit facility has a rate of Euro Interbank Offer Rate ("Euribor") plus 2.95% per year
ClassicPlan Premium Financing [Member] \| JustCBD insurance premium loan [Member]
Line of Credit Facility [Line Items]
Loan agreement, face amount			$ 0.2
Loans payable			$ 0.1
Loan agreement, interest rate	10.10%		10.10%
Principal and interest payments		$ 0.1

LEASES (Schedule of leases) (De

LEASES (Schedule of leases) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease expense	$ 308	$ 136	$ 624	$ 327
Short-term lease expense	62	82	135	233
Total lease expense	370	218	759	560
Other Information
Operating cash flows from operating leases	356	216	720	489
ROU assets obtained in exchange for new operating lease liabilities	$ 0	$ 2,097	$ 97	$ 2,825
Weighted-average remaining lease term in years for operating leases	3 years 4 months 24 days	4 years 6 months	3 years 4 months 24 days	4 years 6 months
Weighted-average discount rate for operating leases	7.70%	8.10%	7.70%	8.10%

LEASES (Schedule of maturities

LEASES (Schedule of maturities of operating lease liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
2023	$ 1,234
2024	425
2025	396
2026	321
2027	48
Total future lease payments	2,424
Less: imputed interest	(247)
Total lease liabilities	2,177
Less: current lease liabilities	(1,124)	$ (1,116)
Total non-current lease liabilities	$ 1,053	$ 1,561

SHARE CAPITAL (Narrative) (Deta

SHARE CAPITAL (Narrative) (Details) - USD ($) $ in Millions			1 Months Ended
SHARE CAPITAL (Narrative) (Details) - USD ($) $ in Millions	Jun. 07, 2023	May 14, 2023	Apr. 26, 2023	Jan. 31, 2023
Capital Unit [Line Items]
Reverse stock split	On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").
Settlement Agreement [Member]
Capital Unit [Line Items]
Number of common shares shares issued				16,250
Value of common shares shares issued				$ 0.1
Separation Agreement [Member]
Capital Unit [Line Items]
Number of common shares shares issued		30,000	80,000
Value of common shares shares issued		$ 0.1	$ 0.4

SHARE BASED COMPENSATION (Narra

SHARE BASED COMPENSATION (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expense (benefit) related to options granted	$ (0.2)	$ 1.3	$ (0.1)	$ 2.8
Remaining stock option cost for nonvested awards	0.1		$ 0.1
Remaining weighted average vesting period			1 year 2 months 12 days
Restricted Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards expense	0.1		$ 0.6
Remaining stock option cost for nonvested awards	$ 0.2		$ 0.2

SHARE BASED COMPENSATION (Sched

SHARE BASED COMPENSATION (Schedule of share options outstanding and exercisable) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, Beginning Balance	290
Number of options, Granted	5
Number of options, Cancelled	(75)
Number of options, Ending Balance	220	290
Number of options, Exercisable balance	203
Weighted average exercise price, Beginning Balance	$ 34.17
Weighted Average Exercise Price, Granted	7
Weighted Average Exercise Price, Cancelled	24.75
Weighted average exercise price, Ending Balance	36.79	$ 34.17
Weighted average exercise price, Exercisable balance	$ 38.86
Weighted average remaining life, Granted	9 years 8 months 12 days
Weighted average remaining life, Cancelled	6 years
Weighted average remaining life, Ending Balance	3 years	4 years 2 months 12 days
Weighted average remaining life, Exercisable	2 years 7 months 6 days
Outstanding Aggregate intrinsic value, Beginning	$ 64
Outstanding Aggregate intrinsic value, Ending	0	$ 64
Outstanding Aggregate intrinsic value, Exercisable	$ 0

SHARE BASED COMPENSATION (Sch_2

SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of restricted stock awards, Beginning Balance \| shares	146
Number of restricted stock awards, Granted \| shares	112
Number of restricted stock awards, Vested \| shares	(38)
Number of restricted stock awards, Cancelled \| shares	(155)
Number of restricted stock awards, Ending Balance \| shares	65
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 13.64
Weighted Average Exercise Price, Granted \| $ / shares	5.85
Weighted Average Exercise Price, Vested \| $ / shares	(13.74)
Weighted Average Exercise Price, Cancelled \| $ / shares	(9.17)
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 11.22

WARRANTS (Schedule of warrants

WARRANTS (Schedule of warrants outstanding) (Details)	6 Months Ended
WARRANTS (Schedule of warrants outstanding) (Details)	Jun. 30, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants Balance, Ending	960
Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants Balance, Beginning	961
Exercised	(1)
Number of warrants Balance, Ending	960
Weighted average exercise price, Beginning Balance \| $ / shares	$ 24.84
Weighted average exercise price, Exercised \| $ / shares	8
Weighted average exercise price, Ending Balance \| $ / shares	$ 24.84

WARRANTS (Schedule of warrant_2

WARRANTS (Schedule of warrants outstanding by date of expiry) (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Warrants outstanding \| shares	960
Exercise price \| $ / shares	$ 24.84
Grant date fair value \| $	$ 10,359
Remaining life in years	4 years 1 month 17 days
November 18, 2026 [Member]
Class of Warrant or Right [Line Items]
Date of expiry	November 18, 2026
Warrants outstanding \| shares	221
Exercise price \| $ / shares	$ 75
Grant date fair value \| $	$ 6,700
Remaining life in years	3 years 4 months 20 days
November 18, 2026 [Member]
Class of Warrant or Right [Line Items]
Date of expiry	November 18, 2026
Warrants outstanding \| shares	66
Exercise price \| $ / shares	$ 8
Grant date fair value \| $	$ 422
Remaining life in years	3 years 4 months 20 days
November 18, 2027 [Member]
Class of Warrant or Right [Line Items]
Date of expiry	November 18, 2027
Warrants outstanding \| shares	23
Exercise price \| $ / shares	$ 66
Grant date fair value \| $	$ 1,055
Remaining life in years	4 years 4 months 20 days
December 8, 2027 [Member]
Class of Warrant or Right [Line Items]
Date of expiry	December 8, 2027
Warrants outstanding \| shares	625
Exercise price \| $ / shares	$ 8
Grant date fair value \| $	$ 2,033
Remaining life in years	4 years 5 months 8 days
December 8, 2027 [Member]
Class of Warrant or Right [Line Items]
Date of expiry	December 8, 2027
Warrants outstanding \| shares	25
Exercise price \| $ / shares	$ 8.8
Grant date fair value \| $	$ 149
Remaining life in years	4 years 5 months 8 days

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	6 Months Ended
	Feb. 03, 2023	Jun. 21, 2022	Jun. 30, 2023
Schedule Of Commitments And Contingencies [Line Items]
Loss contingency provision			$ 389
Additional Legal Disputes [Member]
Schedule Of Commitments And Contingencies [Line Items]
Estimate of possible loss			3,000
Loss contingency provision			3,000
Gerardo Andres Garcia Mendez [Member]
Schedule Of Commitments And Contingencies [Line Items]
Number of shares to be issued pre-one-for three reverse stock split		3,000,000
Purchase price per share		$ 0.05
Franchise Global Health Inc [Member]
Schedule Of Commitments And Contingencies [Line Items]
Maximum limit of indemnification agreement			$ 5,000
Mr Starke [Member]
Schedule Of Commitments And Contingencies [Line Items]
Wrongfully transferred shares	8,831,109
Value of damages sought	$ 3,900

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule Of Commitments And Contingencies [Line Items]
Beginning Balance, Amount	$ 5,044
Payments/Settlements	(281)
Additional provisions	389
Foreign currency translation	36
Ending Balance, Amount	5,188
Termination Benefits [Member]
Schedule Of Commitments And Contingencies [Line Items]
Beginning Balance, Amount	183
Payments/Settlements	(183)
Additional provisions	0
Foreign currency translation	0
Ending Balance, Amount	0
Legal Disputes [Member]
Schedule Of Commitments And Contingencies [Line Items]
Beginning Balance, Amount	3,030
Payments/Settlements	(98)
Additional provisions	0
Foreign currency translation	36
Ending Balance, Amount	2,968
Sales Taxes [Member]
Schedule Of Commitments And Contingencies [Line Items]
Beginning Balance, Amount	1,831
Payments/Settlements	0
Additional provisions	389
Foreign currency translation	0
Ending Balance, Amount	$ 2,220

LOSS PER SHARE (Schedule of ant

LOSS PER SHARE (Schedule of anti-dilutive shares) (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive	1,902	2,054
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive	220	290
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive	960	961
Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive	65	146
JustCBD potential additional shares to settle contingent consideration [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive	657	657

FINANCIAL INSTRUMENTS AND RISK

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments	$ 200	$ 734
Contingent purchase consideration from asset acquisitions and business combinations	2,354	3,547
Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments	0	0
Contingent purchase consideration from asset acquisitions and business combinations	0	0
Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments	0	0
Contingent purchase consideration from asset acquisitions and business combinations	2,354	3,547
Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments	200	734
Contingent purchase consideration from asset acquisitions and business combinations	$ 0	$ 0

SEGMENTED INFORMATION (Schedule

SEGMENTED INFORMATION (Schedule of operation segments information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net Sales	$ 21,460	$ 8,943	$ 40,779	$ 13,144
Net Loss	(36,991)	(23,052)	(40,178)	(29,307)
Assets	30,479		30,479		$ 80,987
Commercial & Wholesale [Member]
Segment Reporting Information [Line Items]
Net Sales	10,797	0	18,755	0
Net Loss	(6,710)	0	(6,737)	0
Assets	11,129		11,129		22,225
House of Brands [Member]
Segment Reporting Information [Line Items]
Net Sales	13,000	10,810	26,765	15,793
Net Loss	(28,763)	(17,354)	(29,118)	(18,016)
Assets	16,317		16,317		48,950
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net Sales	0	0	0	0
Net Loss	(36)	0	(81)	0
Assets	1,159		1,159		3,313
Corp & Eliminations [Member]
Segment Reporting Information [Line Items]
Net Sales	(2,337)	(1,867)	(4,741)	(2,649)
Net Loss	(1,482)	$ (5,698)	(4,242)	$ (11,291)
Assets	$ 1,874		$ 1,874		$ 6,499

SEGMENTED INFORMATION (Schedu_2

SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Net Sales	$ 21,460	$ 8,943	$ 40,779	$ 13,144
UNITED STATES
Segment Reporting Information [Line Items]
Net Sales	10,352	8,679	21,351	12,745
GERMANY
Segment Reporting Information [Line Items]
Net Sales	10,797	0	18,755	0
UNITED KINGDOM
Segment Reporting Information [Line Items]
Net Sales	$ 311	$ 264	$ 673	$ 399

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member] $ in Millions, $ in Millions	Aug. 03, 2023 CAD ($) shares	Jul. 05, 2023 CAD ($)	Jul. 05, 2023 USD ($)
Subsequent Event [Line Items]
Number of restricted shares forfeited	4,000
Number of options share forfeited	51,432
Share Purchase Agreement [Member] \| Lisan Farma Colombia LLC [Member]
Subsequent Event [Line Items]
Purchase price	$ 0.5	$ 0.8	$ 0.6